IPierian gets back to drug discovery basics

As a startup, iPierian boasted some of the world's top experts on stem cells. The impeccable scientific pedigree, however, never translated into the kind of partnering deals the biotech was looking for. And the lack of deals triggered turmoil at the helm. Now new CEO Nancy Stagliano tells San Francisco Business Times writer Ron Leuty the company will return to its IPS cells roots, looking for new treatments for tough neurodegenerative diseases like Alzheimer's and spinal muscular atrophy. "We explored various avenues, including extensive partnering, and concluded that the best place is to put (the company's focus) on neurodegeneration and internal pipelines, with an emphasis on drug discovery," Stagliano tells the SFBT. Report

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.